ReviewMedizinische Klinik, Intensivmedizin und Notfallmedizin2026
[Pharmacotherapy in the geriatric intensive care patient: sedation and anti-infective treatment].
Review in Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older intensive care unit (ICU) patients are particularly vulnerable to adverse drug reactions, delirium, and treatment failure due to age-related changes in pharmacodynamics (PD) and pharmacokinetics (PK), compounded by the dynamic pathophysiology of critical illness. This review focuses on sedatives/analgesics and anti-infective agents. For analgosedation, an analgesia-first strategy, protocol-based light sedation (awake and cooperative whenever feasible), rigorous delirium management, and avoidance of continuous benzodiazepine infusions are recommended. In anti-infective therapy, key priorities include achieving PK/PD targets, daily dose adjustment to current drug clearance, de-escalation, and early therapeutic drug monitoring (vancomycin, aminoglycosides; selectively also β‑lactams).
Indexed as
Identifiers
41817661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.